- Home
- DJCO vs ZURA Comparison
DJCO vs ZURA Comparison
Compare DJCO & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DJCO | ZURA |
|---|---|---|
| Founded | 1987 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Newspapers/Magazines | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 706.2M | 595.9M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | DJCO | ZURA |
|---|---|---|
| Price | $484.32 | $6.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.78 |
| AVG Volume (30 Days) | 89.6K | ★ 494.6K |
| Earning Date | 02-17-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,384,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $348.63 | $0.99 |
| 52 Week High | $674.75 | $7.25 |
Technical Indicators
Market Signals| Indicator | DJCO | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 41.52 | 45.47 |
| Support Level | $481.78 | $5.62 |
| Resistance Level | $495.51 | $6.99 |
| Average True Range (ATR) | 33.92 | 0.50 |
| MACD | -2.38 | -0.13 |
| Stochastic Oscillator | 25.46 | 18.98 |
Price Performance
Historical ComparisonAbout DJCO Daily Journal Corp. (S.C.)
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies which includes Journal Technologies, Inc. and Journal Technologies (Canada) Inc. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Traditional segment.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.